Stryker Corporation $SYK Shares Bought by Rathbones Group PLC

Rathbones Group PLC lifted its position in Stryker Corporation (NYSE:SYK) by 647.9% in the 4th quarter, Holdings Channel.com reports. The fund owned 219,265 shares of the medical technology company’s stock after acquiring an additional 189,948 shares during the period. Rathbones Group PLC’s holdings in Stryker were worth $77,065,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in the stock. VanderPol Investments L.L.C. lifted its holdings in shares of Stryker by 1.4% in the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock worth $732,000 after purchasing an additional 28 shares during the last quarter. Lantz Financial LLC lifted its holdings in shares of Stryker by 5.0% in the 3rd quarter. Lantz Financial LLC now owns 608 shares of the medical technology company’s stock worth $225,000 after purchasing an additional 29 shares during the last quarter. Stonebridge Capital Advisors LLC lifted its holdings in shares of Stryker by 0.4% in the 3rd quarter. Stonebridge Capital Advisors LLC now owns 7,198 shares of the medical technology company’s stock worth $2,661,000 after purchasing an additional 29 shares during the last quarter. Tcfg Wealth Management LLC lifted its holdings in shares of Stryker by 2.7% in the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after purchasing an additional 29 shares during the last quarter. Finally, Mechanics Financial Corp lifted its holdings in shares of Stryker by 1.2% in the 4th quarter. Mechanics Financial Corp now owns 2,458 shares of the medical technology company’s stock worth $864,000 after purchasing an additional 30 shares during the last quarter. Institutional investors own 77.09% of the company’s stock.

Insider Activity at Stryker

In other news, VP M Kathryn Fink sold 3,500 shares of the business’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the sale, the vice president owned 177 shares of the company’s stock, valued at approximately $50,170.65. The trade was a 95.19% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 4.60% of the company’s stock.

Stryker Stock Up 1.0%

Shares of Stryker stock opened at $320.99 on Thursday. The business’s fifty day moving average price is $326.71 and its two-hundred day moving average price is $350.36. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.11 and a quick ratio of 1.25. The company has a market capitalization of $123.06 billion, a P/E ratio of 37.15, a PEG ratio of 2.00 and a beta of 0.80. Stryker Corporation has a 1-year low of $281.00 and a 1-year high of $404.87.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share for the quarter, missing the consensus estimate of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm’s revenue was up 2.6% on a year-over-year basis. During the same period in the previous year, the firm earned $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, research analysts forecast that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s payout ratio is presently 40.74%.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Canaccord Genuity Group cut their price target on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a report on Friday, May 1st. William Blair reissued an “outperform” rating on shares of Stryker in a report on Thursday, March 5th. Needham & Company LLC cut their price target on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Barclays cut their price target on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a report on Monday, May 4th. Finally, JPMorgan Chase & Co. cut their price target on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a report on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $395.48.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.